Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 2 ... drug sunitinib malate, but other successful examples without VEGF inhibition include imatinib mesylate. The report includes a compilation of current active projects in research ...
2009 NOV 23 ... "We aimed to compare the cytogenetic and molecular analyses in the assessment of imatinib mesylate response in patients suffering the chronic phase of chronic myelocytic leukemia who were ...
2009 OCT 12 ... Pavlovsky and colleagues published their study in Pharmacotherapy (Imatinib Mesylate Pharmacokinetics Before and After Sleeve Gastrectomy in a Morbidly Obese Patient with ...
2009 NOV 23 ... carcinomas (TC) but infrequently in thymomas. Anecdotal experience suggests activity of imatinib mesylate in TC," scientists in the United States report. "with unresectable World ...
2009 OCT 19 ... of Clinical Oncology show that adding continuous daily doses of a targeted drug called imatinib mesylate to regular chemotherapy more than doubled three-year survival rates for children with a ...
2009 NOV 2 ... the first head-to-head comparison with the company's groundbreaking drug Gleevec® (imatinib mesylate) tablets*. Tasigna produced faster and deeper responses than Gleevec when given as ...
2009 NOV 2 ... in the first head-to-head comparison with the company's groundbreaking drug Gleevec=AE (imatinib mesylate) tablets*. Tasigna produced faster and deeper responses than Gleevec when given as ...
2009 OCT 5 ... of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate and advanced / metastatic renal cell carcinoma (RCC). Sutent works by ...
2009 NOV 23 ... t(9;22), which leads to the fusion-protein BCR-ABL. Prior to the development of imatinib mesylate (Gleevec), treatment was limited and provided only limited survival benefit," ...
2009 SEP 21 ... pump inhibitor on the pharmacokinetics of imatinib,' new data in pharmacokinetics. "Imatinib mesylate (Gleevec/Glivec), which has revolutionized the treatment of chronic myeloid leukemias ...
2009 NOV 16 ... could be completely blocked by adding a c-kit/tyrosine kinase inhibitor, Gleevec (imatinib mesylate; Novartis International, Basel, Switzerland, http://www.novartis.com), to the culture. ...
2009 SEP 28 ... in the resected lung lesion. The remaining lung metastases responded to treatment with imatinib mesylate, but the treatment was discontinued because of toxicity. The patient remains under ...
2009 OCT 5 ... Criteria in Solid Tumors Predicts Survival in Advanced GI Stromal Tumors Treated With Imatinib Mesylate: The Intergroup EORTC-ISG-AGITG Phase III Trial. Journal of Clinical Oncology, ...
2009 NOV 16 ... to recent research published in the journal Molecular Cancer, "The development of Imatinib Mesylate (IM), the first specific inhibitor of BCR-ABLI, has had a major impact in patients with ...
